SELL and COVID-19: In patients with moderate COVID-19, there was a significant upregulation of L-selectin (SELL/CD62L) and C-X-C Motif Chemokine Receptor 2 (CXCR2), indicating an activated state aimed at moderate inflammation control and pathogen clearance (Fig 2C).